Global DPT Vaccines research

DPT Vaccines Comprehensive Study by Type (DPaT, DTwP, Tdap), Application (Diphtheria, Tetanus, Pertussis, Others), Vaccine Type (Whole-Cell Vaccine, Acellular Vaccine), End-User (Adult, Pediatric) Players and Region - Global Market Outlook to 2028

DPT Vaccines Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About DPT Vaccines
Although different combinations may contain the same toxoids or antigens each vaccine may differ substantially according to the toxoid or antigen dose, number of pertussis components (for acellular vaccines), method of purification and inactivation of the toxins and incorporation of adjuvants and excipients. All of these factors may have an influence on the reactogenicity of different DTP vaccine combinations. According to WHO, developed countries prefer to purchase a component of the DPT vaccines such as procure acellular pertussis (DTaP), while most developing countries purchase vaccines with whole-cell pertussis (DTwP) components.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


DPT Vaccines is highly competitive, with several key players dominating the industry. The market players are focused on developing a variety of features and benefits to meet the needs. Thus, constantly introducing new innovation in processing to meet the changing needs and preferences of consumers. The companies are also planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Analyst at AMA Research estimates that European Players will contribute the maximum growth to Global DPT Vaccines market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Merck & Co., Inc. (United States), Sanofi (France), GSK (United Kingdom), Wyeth (United States), Serum Institute of India Pvt. Ltd. (India), Pfizer Inc. (United States), Johnson & Johnson (United States), Novartis AG (Switzerland), AstraZeneca (United Kingdom), Emergent BioSolutions Inc. (United States) and Astellas Pharma, Inc. (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Chiron Pharmaceutical Pvt Ltd (India) and Lanzhou Institute of Biological Products (China).

Segmentation Overview
AMA Research has segmented the market of Global DPT Vaccines market by Type (DPaT, DTwP and Tdap), Application (Diphtheria, Tetanus, Pertussis and Others) and Region.



On the basis of geography, the market of DPT Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Vaccine Type, the sub-segment i.e. Whole-Cell Vaccine will boost the DPT Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-User, the sub-segment i.e. Adult will boost the DPT Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Advancements in Vaccine Delivery Devices and Development of Technologically Advanced Vaccines

Market Growth Drivers:
High Prevalence of Infectious Diseases and Rising Government Support for Vaccine Development

Challenges:
Product Recall Due to Stringent Government Regulation and Side Effects such as Redness, Irritation Due to DPT vaccine

Restraints:
High Cost for Development of Vaccine

Opportunities:
Increasing Government Initiatives in Research & Development

Market Leaders and their expansionary development strategies
In January 2020, Merck Completes Acquisition of ArQule. At the completion of the merger, ArQule became a wholly-owned subsidiary of Merck. Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases.
In November 2023, Indian immunologicals launched measles and rubella vaccines for Childrens. The Vaccine has been proven to be safe and effective through extensive human clinical trials.


Key Target Audience
Manufacturers of DPT Vaccines, Suppliers of DPT Vaccines, Pharmaceutical Industry, R & D Companies, Research Laboratories, Medical Institutes, Pharmaceutical Industry and Governmental Bodies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • DPaT
  • DTwP
  • Tdap
By Application
  • Diphtheria
  • Tetanus
  • Pertussis
  • Others
By Vaccine Type
  • Whole-Cell Vaccine
  • Acellular Vaccine

By End-User
  • Adult
  • Pediatric

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Prevalence of Infectious Diseases
      • 3.2.2. Rising Government Support for Vaccine Development
    • 3.3. Market Challenges
      • 3.3.1. Product Recall Due to Stringent Government Regulation
      • 3.3.2. Side Effects such as Redness, Irritation Due to DPT vaccine
    • 3.4. Market Trends
      • 3.4.1. Advancements in Vaccine Delivery Devices
      • 3.4.2. Development of Technologically Advanced Vaccines
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global DPT Vaccines, by Type, Application, Vaccine Type, End-User and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global DPT Vaccines (Value)
      • 5.2.1. Global DPT Vaccines by: Type (Value)
        • 5.2.1.1. DPaT
        • 5.2.1.2. DTwP
        • 5.2.1.3. Tdap
      • 5.2.2. Global DPT Vaccines by: Application (Value)
        • 5.2.2.1. Diphtheria
        • 5.2.2.2. Tetanus
        • 5.2.2.3. Pertussis
        • 5.2.2.4. Others
      • 5.2.3. Global DPT Vaccines by: Vaccine Type (Value)
        • 5.2.3.1. Whole-Cell Vaccine
        • 5.2.3.2. Acellular Vaccine
      • 5.2.4. Global DPT Vaccines by: End-User (Value)
        • 5.2.4.1. Adult
        • 5.2.4.2. Pediatric
      • 5.2.5. Global DPT Vaccines Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global DPT Vaccines (Volume)
      • 5.3.1. Global DPT Vaccines by: Type (Volume)
        • 5.3.1.1. DPaT
        • 5.3.1.2. DTwP
        • 5.3.1.3. Tdap
      • 5.3.2. Global DPT Vaccines by: Application (Volume)
        • 5.3.2.1. Diphtheria
        • 5.3.2.2. Tetanus
        • 5.3.2.3. Pertussis
        • 5.3.2.4. Others
      • 5.3.3. Global DPT Vaccines by: Vaccine Type (Volume)
        • 5.3.3.1. Whole-Cell Vaccine
        • 5.3.3.2. Acellular Vaccine
      • 5.3.4. Global DPT Vaccines by: End-User (Volume)
        • 5.3.4.1. Adult
        • 5.3.4.2. Pediatric
      • 5.3.5. Global DPT Vaccines Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global DPT Vaccines (Price)
      • 5.4.1. Global DPT Vaccines by: Type (Price)
  • 6. DPT Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co., Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GSK (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Wyeth (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Serum Institute of India Pvt. Ltd. (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AstraZeneca (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Emergent BioSolutions Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Astellas Pharma, Inc. (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global DPT Vaccines Sale, by Type, Application, Vaccine Type, End-User and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global DPT Vaccines (Value)
      • 7.2.1. Global DPT Vaccines by: Type (Value)
        • 7.2.1.1. DPaT
        • 7.2.1.2. DTwP
        • 7.2.1.3. Tdap
      • 7.2.2. Global DPT Vaccines by: Application (Value)
        • 7.2.2.1. Diphtheria
        • 7.2.2.2. Tetanus
        • 7.2.2.3. Pertussis
        • 7.2.2.4. Others
      • 7.2.3. Global DPT Vaccines by: Vaccine Type (Value)
        • 7.2.3.1. Whole-Cell Vaccine
        • 7.2.3.2. Acellular Vaccine
      • 7.2.4. Global DPT Vaccines by: End-User (Value)
        • 7.2.4.1. Adult
        • 7.2.4.2. Pediatric
      • 7.2.5. Global DPT Vaccines Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global DPT Vaccines (Volume)
      • 7.3.1. Global DPT Vaccines by: Type (Volume)
        • 7.3.1.1. DPaT
        • 7.3.1.2. DTwP
        • 7.3.1.3. Tdap
      • 7.3.2. Global DPT Vaccines by: Application (Volume)
        • 7.3.2.1. Diphtheria
        • 7.3.2.2. Tetanus
        • 7.3.2.3. Pertussis
        • 7.3.2.4. Others
      • 7.3.3. Global DPT Vaccines by: Vaccine Type (Volume)
        • 7.3.3.1. Whole-Cell Vaccine
        • 7.3.3.2. Acellular Vaccine
      • 7.3.4. Global DPT Vaccines by: End-User (Volume)
        • 7.3.4.1. Adult
        • 7.3.4.2. Pediatric
      • 7.3.5. Global DPT Vaccines Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global DPT Vaccines (Price)
      • 7.4.1. Global DPT Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. DPT Vaccines: by Type(USD Million)
  • Table 2. DPT Vaccines DPaT , by Region USD Million (2017-2022)
  • Table 3. DPT Vaccines DTwP , by Region USD Million (2017-2022)
  • Table 4. DPT Vaccines Tdap , by Region USD Million (2017-2022)
  • Table 5. DPT Vaccines: by Application(USD Million)
  • Table 6. DPT Vaccines Diphtheria , by Region USD Million (2017-2022)
  • Table 7. DPT Vaccines Tetanus , by Region USD Million (2017-2022)
  • Table 8. DPT Vaccines Pertussis , by Region USD Million (2017-2022)
  • Table 9. DPT Vaccines Others , by Region USD Million (2017-2022)
  • Table 10. DPT Vaccines: by Vaccine Type(USD Million)
  • Table 11. DPT Vaccines Whole-Cell Vaccine , by Region USD Million (2017-2022)
  • Table 12. DPT Vaccines Acellular Vaccine , by Region USD Million (2017-2022)
  • Table 13. DPT Vaccines: by End-User(USD Million)
  • Table 14. DPT Vaccines Adult , by Region USD Million (2017-2022)
  • Table 15. DPT Vaccines Pediatric , by Region USD Million (2017-2022)
  • Table 16. South America DPT Vaccines, by Country USD Million (2017-2022)
  • Table 17. South America DPT Vaccines, by Type USD Million (2017-2022)
  • Table 18. South America DPT Vaccines, by Application USD Million (2017-2022)
  • Table 19. South America DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 20. South America DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 21. Brazil DPT Vaccines, by Type USD Million (2017-2022)
  • Table 22. Brazil DPT Vaccines, by Application USD Million (2017-2022)
  • Table 23. Brazil DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 24. Brazil DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 25. Argentina DPT Vaccines, by Type USD Million (2017-2022)
  • Table 26. Argentina DPT Vaccines, by Application USD Million (2017-2022)
  • Table 27. Argentina DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 28. Argentina DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 29. Rest of South America DPT Vaccines, by Type USD Million (2017-2022)
  • Table 30. Rest of South America DPT Vaccines, by Application USD Million (2017-2022)
  • Table 31. Rest of South America DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 32. Rest of South America DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 33. Asia Pacific DPT Vaccines, by Country USD Million (2017-2022)
  • Table 34. Asia Pacific DPT Vaccines, by Type USD Million (2017-2022)
  • Table 35. Asia Pacific DPT Vaccines, by Application USD Million (2017-2022)
  • Table 36. Asia Pacific DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 37. Asia Pacific DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 38. China DPT Vaccines, by Type USD Million (2017-2022)
  • Table 39. China DPT Vaccines, by Application USD Million (2017-2022)
  • Table 40. China DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 41. China DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 42. Japan DPT Vaccines, by Type USD Million (2017-2022)
  • Table 43. Japan DPT Vaccines, by Application USD Million (2017-2022)
  • Table 44. Japan DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 45. Japan DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 46. India DPT Vaccines, by Type USD Million (2017-2022)
  • Table 47. India DPT Vaccines, by Application USD Million (2017-2022)
  • Table 48. India DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 49. India DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 50. South Korea DPT Vaccines, by Type USD Million (2017-2022)
  • Table 51. South Korea DPT Vaccines, by Application USD Million (2017-2022)
  • Table 52. South Korea DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 53. South Korea DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 54. Taiwan DPT Vaccines, by Type USD Million (2017-2022)
  • Table 55. Taiwan DPT Vaccines, by Application USD Million (2017-2022)
  • Table 56. Taiwan DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 57. Taiwan DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 58. Australia DPT Vaccines, by Type USD Million (2017-2022)
  • Table 59. Australia DPT Vaccines, by Application USD Million (2017-2022)
  • Table 60. Australia DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 61. Australia DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 62. Rest of Asia-Pacific DPT Vaccines, by Type USD Million (2017-2022)
  • Table 63. Rest of Asia-Pacific DPT Vaccines, by Application USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 66. Europe DPT Vaccines, by Country USD Million (2017-2022)
  • Table 67. Europe DPT Vaccines, by Type USD Million (2017-2022)
  • Table 68. Europe DPT Vaccines, by Application USD Million (2017-2022)
  • Table 69. Europe DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 70. Europe DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 71. Germany DPT Vaccines, by Type USD Million (2017-2022)
  • Table 72. Germany DPT Vaccines, by Application USD Million (2017-2022)
  • Table 73. Germany DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 74. Germany DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 75. France DPT Vaccines, by Type USD Million (2017-2022)
  • Table 76. France DPT Vaccines, by Application USD Million (2017-2022)
  • Table 77. France DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 78. France DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 79. Italy DPT Vaccines, by Type USD Million (2017-2022)
  • Table 80. Italy DPT Vaccines, by Application USD Million (2017-2022)
  • Table 81. Italy DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 82. Italy DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 83. United Kingdom DPT Vaccines, by Type USD Million (2017-2022)
  • Table 84. United Kingdom DPT Vaccines, by Application USD Million (2017-2022)
  • Table 85. United Kingdom DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 86. United Kingdom DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 87. Netherlands DPT Vaccines, by Type USD Million (2017-2022)
  • Table 88. Netherlands DPT Vaccines, by Application USD Million (2017-2022)
  • Table 89. Netherlands DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 90. Netherlands DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 91. Rest of Europe DPT Vaccines, by Type USD Million (2017-2022)
  • Table 92. Rest of Europe DPT Vaccines, by Application USD Million (2017-2022)
  • Table 93. Rest of Europe DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 94. Rest of Europe DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 95. MEA DPT Vaccines, by Country USD Million (2017-2022)
  • Table 96. MEA DPT Vaccines, by Type USD Million (2017-2022)
  • Table 97. MEA DPT Vaccines, by Application USD Million (2017-2022)
  • Table 98. MEA DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 99. MEA DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 100. Middle East DPT Vaccines, by Type USD Million (2017-2022)
  • Table 101. Middle East DPT Vaccines, by Application USD Million (2017-2022)
  • Table 102. Middle East DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 103. Middle East DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 104. Africa DPT Vaccines, by Type USD Million (2017-2022)
  • Table 105. Africa DPT Vaccines, by Application USD Million (2017-2022)
  • Table 106. Africa DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 107. Africa DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 108. North America DPT Vaccines, by Country USD Million (2017-2022)
  • Table 109. North America DPT Vaccines, by Type USD Million (2017-2022)
  • Table 110. North America DPT Vaccines, by Application USD Million (2017-2022)
  • Table 111. North America DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 112. North America DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 113. United States DPT Vaccines, by Type USD Million (2017-2022)
  • Table 114. United States DPT Vaccines, by Application USD Million (2017-2022)
  • Table 115. United States DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 116. United States DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 117. Canada DPT Vaccines, by Type USD Million (2017-2022)
  • Table 118. Canada DPT Vaccines, by Application USD Million (2017-2022)
  • Table 119. Canada DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 120. Canada DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 121. Mexico DPT Vaccines, by Type USD Million (2017-2022)
  • Table 122. Mexico DPT Vaccines, by Application USD Million (2017-2022)
  • Table 123. Mexico DPT Vaccines, by Vaccine Type USD Million (2017-2022)
  • Table 124. Mexico DPT Vaccines, by End-User USD Million (2017-2022)
  • Table 125. DPT Vaccines Sales: by Type(K Tons)
  • Table 126. DPT Vaccines Sales DPaT , by Region K Tons (2017-2022)
  • Table 127. DPT Vaccines Sales DTwP , by Region K Tons (2017-2022)
  • Table 128. DPT Vaccines Sales Tdap , by Region K Tons (2017-2022)
  • Table 129. DPT Vaccines Sales: by Application(K Tons)
  • Table 130. DPT Vaccines Sales Diphtheria , by Region K Tons (2017-2022)
  • Table 131. DPT Vaccines Sales Tetanus , by Region K Tons (2017-2022)
  • Table 132. DPT Vaccines Sales Pertussis , by Region K Tons (2017-2022)
  • Table 133. DPT Vaccines Sales Others , by Region K Tons (2017-2022)
  • Table 134. DPT Vaccines Sales: by Vaccine Type(K Tons)
  • Table 135. DPT Vaccines Sales Whole-Cell Vaccine , by Region K Tons (2017-2022)
  • Table 136. DPT Vaccines Sales Acellular Vaccine , by Region K Tons (2017-2022)
  • Table 137. DPT Vaccines Sales: by End-User(K Tons)
  • Table 138. DPT Vaccines Sales Adult , by Region K Tons (2017-2022)
  • Table 139. DPT Vaccines Sales Pediatric , by Region K Tons (2017-2022)
  • Table 140. South America DPT Vaccines Sales, by Country K Tons (2017-2022)
  • Table 141. South America DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 142. South America DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 143. South America DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 144. South America DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 145. Brazil DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 146. Brazil DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 147. Brazil DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 148. Brazil DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 149. Argentina DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 150. Argentina DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 151. Argentina DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 152. Argentina DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 153. Rest of South America DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 154. Rest of South America DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 155. Rest of South America DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 156. Rest of South America DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 157. Asia Pacific DPT Vaccines Sales, by Country K Tons (2017-2022)
  • Table 158. Asia Pacific DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 159. Asia Pacific DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 160. Asia Pacific DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 161. Asia Pacific DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 162. China DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 163. China DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 164. China DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 165. China DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 166. Japan DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 167. Japan DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 168. Japan DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 169. Japan DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 170. India DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 171. India DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 172. India DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 173. India DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 174. South Korea DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 175. South Korea DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 176. South Korea DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 177. South Korea DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 178. Taiwan DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 179. Taiwan DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 180. Taiwan DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 181. Taiwan DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 182. Australia DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 183. Australia DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 184. Australia DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 185. Australia DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 186. Rest of Asia-Pacific DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 187. Rest of Asia-Pacific DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 188. Rest of Asia-Pacific DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 189. Rest of Asia-Pacific DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 190. Europe DPT Vaccines Sales, by Country K Tons (2017-2022)
  • Table 191. Europe DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 192. Europe DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 193. Europe DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 194. Europe DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 195. Germany DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 196. Germany DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 197. Germany DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 198. Germany DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 199. France DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 200. France DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 201. France DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 202. France DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 203. Italy DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 204. Italy DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 205. Italy DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 206. Italy DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 207. United Kingdom DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 208. United Kingdom DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 209. United Kingdom DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 210. United Kingdom DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 211. Netherlands DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 212. Netherlands DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 213. Netherlands DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 214. Netherlands DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 215. Rest of Europe DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 216. Rest of Europe DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 217. Rest of Europe DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 218. Rest of Europe DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 219. MEA DPT Vaccines Sales, by Country K Tons (2017-2022)
  • Table 220. MEA DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 221. MEA DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 222. MEA DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 223. MEA DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 224. Middle East DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 225. Middle East DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 226. Middle East DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 227. Middle East DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 228. Africa DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 229. Africa DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 230. Africa DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 231. Africa DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 232. North America DPT Vaccines Sales, by Country K Tons (2017-2022)
  • Table 233. North America DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 234. North America DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 235. North America DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 236. North America DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 237. United States DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 238. United States DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 239. United States DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 240. United States DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 241. Canada DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 242. Canada DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 243. Canada DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 244. Canada DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 245. Mexico DPT Vaccines Sales, by Type K Tons (2017-2022)
  • Table 246. Mexico DPT Vaccines Sales, by Application K Tons (2017-2022)
  • Table 247. Mexico DPT Vaccines Sales, by Vaccine Type K Tons (2017-2022)
  • Table 248. Mexico DPT Vaccines Sales, by End-User K Tons (2017-2022)
  • Table 249. DPT Vaccines: by Type(USD/Units)
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. DPT Vaccines: by Type(USD Million)
  • Table 262. DPT Vaccines DPaT , by Region USD Million (2023-2028)
  • Table 263. DPT Vaccines DTwP , by Region USD Million (2023-2028)
  • Table 264. DPT Vaccines Tdap , by Region USD Million (2023-2028)
  • Table 265. DPT Vaccines: by Application(USD Million)
  • Table 266. DPT Vaccines Diphtheria , by Region USD Million (2023-2028)
  • Table 267. DPT Vaccines Tetanus , by Region USD Million (2023-2028)
  • Table 268. DPT Vaccines Pertussis , by Region USD Million (2023-2028)
  • Table 269. DPT Vaccines Others , by Region USD Million (2023-2028)
  • Table 270. DPT Vaccines: by Vaccine Type(USD Million)
  • Table 271. DPT Vaccines Whole-Cell Vaccine , by Region USD Million (2023-2028)
  • Table 272. DPT Vaccines Acellular Vaccine , by Region USD Million (2023-2028)
  • Table 273. DPT Vaccines: by End-User(USD Million)
  • Table 274. DPT Vaccines Adult , by Region USD Million (2023-2028)
  • Table 275. DPT Vaccines Pediatric , by Region USD Million (2023-2028)
  • Table 276. South America DPT Vaccines, by Country USD Million (2023-2028)
  • Table 277. South America DPT Vaccines, by Type USD Million (2023-2028)
  • Table 278. South America DPT Vaccines, by Application USD Million (2023-2028)
  • Table 279. South America DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 280. South America DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 281. Brazil DPT Vaccines, by Type USD Million (2023-2028)
  • Table 282. Brazil DPT Vaccines, by Application USD Million (2023-2028)
  • Table 283. Brazil DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 284. Brazil DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 285. Argentina DPT Vaccines, by Type USD Million (2023-2028)
  • Table 286. Argentina DPT Vaccines, by Application USD Million (2023-2028)
  • Table 287. Argentina DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 288. Argentina DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 289. Rest of South America DPT Vaccines, by Type USD Million (2023-2028)
  • Table 290. Rest of South America DPT Vaccines, by Application USD Million (2023-2028)
  • Table 291. Rest of South America DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 292. Rest of South America DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 293. Asia Pacific DPT Vaccines, by Country USD Million (2023-2028)
  • Table 294. Asia Pacific DPT Vaccines, by Type USD Million (2023-2028)
  • Table 295. Asia Pacific DPT Vaccines, by Application USD Million (2023-2028)
  • Table 296. Asia Pacific DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 297. Asia Pacific DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 298. China DPT Vaccines, by Type USD Million (2023-2028)
  • Table 299. China DPT Vaccines, by Application USD Million (2023-2028)
  • Table 300. China DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 301. China DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 302. Japan DPT Vaccines, by Type USD Million (2023-2028)
  • Table 303. Japan DPT Vaccines, by Application USD Million (2023-2028)
  • Table 304. Japan DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 305. Japan DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 306. India DPT Vaccines, by Type USD Million (2023-2028)
  • Table 307. India DPT Vaccines, by Application USD Million (2023-2028)
  • Table 308. India DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 309. India DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 310. South Korea DPT Vaccines, by Type USD Million (2023-2028)
  • Table 311. South Korea DPT Vaccines, by Application USD Million (2023-2028)
  • Table 312. South Korea DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 313. South Korea DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 314. Taiwan DPT Vaccines, by Type USD Million (2023-2028)
  • Table 315. Taiwan DPT Vaccines, by Application USD Million (2023-2028)
  • Table 316. Taiwan DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 317. Taiwan DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 318. Australia DPT Vaccines, by Type USD Million (2023-2028)
  • Table 319. Australia DPT Vaccines, by Application USD Million (2023-2028)
  • Table 320. Australia DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 321. Australia DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 322. Rest of Asia-Pacific DPT Vaccines, by Type USD Million (2023-2028)
  • Table 323. Rest of Asia-Pacific DPT Vaccines, by Application USD Million (2023-2028)
  • Table 324. Rest of Asia-Pacific DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 325. Rest of Asia-Pacific DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 326. Europe DPT Vaccines, by Country USD Million (2023-2028)
  • Table 327. Europe DPT Vaccines, by Type USD Million (2023-2028)
  • Table 328. Europe DPT Vaccines, by Application USD Million (2023-2028)
  • Table 329. Europe DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 330. Europe DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 331. Germany DPT Vaccines, by Type USD Million (2023-2028)
  • Table 332. Germany DPT Vaccines, by Application USD Million (2023-2028)
  • Table 333. Germany DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 334. Germany DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 335. France DPT Vaccines, by Type USD Million (2023-2028)
  • Table 336. France DPT Vaccines, by Application USD Million (2023-2028)
  • Table 337. France DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 338. France DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 339. Italy DPT Vaccines, by Type USD Million (2023-2028)
  • Table 340. Italy DPT Vaccines, by Application USD Million (2023-2028)
  • Table 341. Italy DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 342. Italy DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 343. United Kingdom DPT Vaccines, by Type USD Million (2023-2028)
  • Table 344. United Kingdom DPT Vaccines, by Application USD Million (2023-2028)
  • Table 345. United Kingdom DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 346. United Kingdom DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 347. Netherlands DPT Vaccines, by Type USD Million (2023-2028)
  • Table 348. Netherlands DPT Vaccines, by Application USD Million (2023-2028)
  • Table 349. Netherlands DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 350. Netherlands DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 351. Rest of Europe DPT Vaccines, by Type USD Million (2023-2028)
  • Table 352. Rest of Europe DPT Vaccines, by Application USD Million (2023-2028)
  • Table 353. Rest of Europe DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 354. Rest of Europe DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 355. MEA DPT Vaccines, by Country USD Million (2023-2028)
  • Table 356. MEA DPT Vaccines, by Type USD Million (2023-2028)
  • Table 357. MEA DPT Vaccines, by Application USD Million (2023-2028)
  • Table 358. MEA DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 359. MEA DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 360. Middle East DPT Vaccines, by Type USD Million (2023-2028)
  • Table 361. Middle East DPT Vaccines, by Application USD Million (2023-2028)
  • Table 362. Middle East DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 363. Middle East DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 364. Africa DPT Vaccines, by Type USD Million (2023-2028)
  • Table 365. Africa DPT Vaccines, by Application USD Million (2023-2028)
  • Table 366. Africa DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 367. Africa DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 368. North America DPT Vaccines, by Country USD Million (2023-2028)
  • Table 369. North America DPT Vaccines, by Type USD Million (2023-2028)
  • Table 370. North America DPT Vaccines, by Application USD Million (2023-2028)
  • Table 371. North America DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 372. North America DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 373. United States DPT Vaccines, by Type USD Million (2023-2028)
  • Table 374. United States DPT Vaccines, by Application USD Million (2023-2028)
  • Table 375. United States DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 376. United States DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 377. Canada DPT Vaccines, by Type USD Million (2023-2028)
  • Table 378. Canada DPT Vaccines, by Application USD Million (2023-2028)
  • Table 379. Canada DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 380. Canada DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 381. Mexico DPT Vaccines, by Type USD Million (2023-2028)
  • Table 382. Mexico DPT Vaccines, by Application USD Million (2023-2028)
  • Table 383. Mexico DPT Vaccines, by Vaccine Type USD Million (2023-2028)
  • Table 384. Mexico DPT Vaccines, by End-User USD Million (2023-2028)
  • Table 385. DPT Vaccines Sales: by Type(K Tons)
  • Table 386. DPT Vaccines Sales DPaT , by Region K Tons (2023-2028)
  • Table 387. DPT Vaccines Sales DTwP , by Region K Tons (2023-2028)
  • Table 388. DPT Vaccines Sales Tdap , by Region K Tons (2023-2028)
  • Table 389. DPT Vaccines Sales: by Application(K Tons)
  • Table 390. DPT Vaccines Sales Diphtheria , by Region K Tons (2023-2028)
  • Table 391. DPT Vaccines Sales Tetanus , by Region K Tons (2023-2028)
  • Table 392. DPT Vaccines Sales Pertussis , by Region K Tons (2023-2028)
  • Table 393. DPT Vaccines Sales Others , by Region K Tons (2023-2028)
  • Table 394. DPT Vaccines Sales: by Vaccine Type(K Tons)
  • Table 395. DPT Vaccines Sales Whole-Cell Vaccine , by Region K Tons (2023-2028)
  • Table 396. DPT Vaccines Sales Acellular Vaccine , by Region K Tons (2023-2028)
  • Table 397. DPT Vaccines Sales: by End-User(K Tons)
  • Table 398. DPT Vaccines Sales Adult , by Region K Tons (2023-2028)
  • Table 399. DPT Vaccines Sales Pediatric , by Region K Tons (2023-2028)
  • Table 400. South America DPT Vaccines Sales, by Country K Tons (2023-2028)
  • Table 401. South America DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 402. South America DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 403. South America DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 404. South America DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 405. Brazil DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 406. Brazil DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 407. Brazil DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 408. Brazil DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 409. Argentina DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 410. Argentina DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 411. Argentina DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 412. Argentina DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 413. Rest of South America DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 414. Rest of South America DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 415. Rest of South America DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 416. Rest of South America DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 417. Asia Pacific DPT Vaccines Sales, by Country K Tons (2023-2028)
  • Table 418. Asia Pacific DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 419. Asia Pacific DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 420. Asia Pacific DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 421. Asia Pacific DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 422. China DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 423. China DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 424. China DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 425. China DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 426. Japan DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 427. Japan DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 428. Japan DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 429. Japan DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 430. India DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 431. India DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 432. India DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 433. India DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 434. South Korea DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 435. South Korea DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 436. South Korea DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 437. South Korea DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 438. Taiwan DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 439. Taiwan DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 440. Taiwan DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 441. Taiwan DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 442. Australia DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 443. Australia DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 444. Australia DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 445. Australia DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 446. Rest of Asia-Pacific DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 447. Rest of Asia-Pacific DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 448. Rest of Asia-Pacific DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 449. Rest of Asia-Pacific DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 450. Europe DPT Vaccines Sales, by Country K Tons (2023-2028)
  • Table 451. Europe DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 452. Europe DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 453. Europe DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 454. Europe DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 455. Germany DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 456. Germany DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 457. Germany DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 458. Germany DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 459. France DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 460. France DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 461. France DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 462. France DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 463. Italy DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 464. Italy DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 465. Italy DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 466. Italy DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 467. United Kingdom DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 468. United Kingdom DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 469. United Kingdom DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 470. United Kingdom DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 471. Netherlands DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 472. Netherlands DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 473. Netherlands DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 474. Netherlands DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 475. Rest of Europe DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 476. Rest of Europe DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 477. Rest of Europe DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 478. Rest of Europe DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 479. MEA DPT Vaccines Sales, by Country K Tons (2023-2028)
  • Table 480. MEA DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 481. MEA DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 482. MEA DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 483. MEA DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 484. Middle East DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 485. Middle East DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 486. Middle East DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 487. Middle East DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 488. Africa DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 489. Africa DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 490. Africa DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 491. Africa DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 492. North America DPT Vaccines Sales, by Country K Tons (2023-2028)
  • Table 493. North America DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 494. North America DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 495. North America DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 496. North America DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 497. United States DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 498. United States DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 499. United States DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 500. United States DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 501. Canada DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 502. Canada DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 503. Canada DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 504. Canada DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 505. Mexico DPT Vaccines Sales, by Type K Tons (2023-2028)
  • Table 506. Mexico DPT Vaccines Sales, by Application K Tons (2023-2028)
  • Table 507. Mexico DPT Vaccines Sales, by Vaccine Type K Tons (2023-2028)
  • Table 508. Mexico DPT Vaccines Sales, by End-User K Tons (2023-2028)
  • Table 509. DPT Vaccines: by Type(USD/Units)
  • Table 510. Research Programs/Design for This Report
  • Table 511. Key Data Information from Secondary Sources
  • Table 512. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global DPT Vaccines: by Type USD Million (2017-2022)
  • Figure 5. Global DPT Vaccines: by Application USD Million (2017-2022)
  • Figure 6. Global DPT Vaccines: by Vaccine Type USD Million (2017-2022)
  • Figure 7. Global DPT Vaccines: by End-User USD Million (2017-2022)
  • Figure 8. South America DPT Vaccines Share (%), by Country
  • Figure 9. Asia Pacific DPT Vaccines Share (%), by Country
  • Figure 10. Europe DPT Vaccines Share (%), by Country
  • Figure 11. MEA DPT Vaccines Share (%), by Country
  • Figure 12. North America DPT Vaccines Share (%), by Country
  • Figure 13. Global DPT Vaccines: by Type K Tons (2017-2022)
  • Figure 14. Global DPT Vaccines: by Application K Tons (2017-2022)
  • Figure 15. Global DPT Vaccines: by Vaccine Type K Tons (2017-2022)
  • Figure 16. Global DPT Vaccines: by End-User K Tons (2017-2022)
  • Figure 17. South America DPT Vaccines Share (%), by Country
  • Figure 18. Asia Pacific DPT Vaccines Share (%), by Country
  • Figure 19. Europe DPT Vaccines Share (%), by Country
  • Figure 20. MEA DPT Vaccines Share (%), by Country
  • Figure 21. North America DPT Vaccines Share (%), by Country
  • Figure 22. Global DPT Vaccines: by Type USD/Units (2017-2022)
  • Figure 23. Global DPT Vaccines share by Players 2022 (%)
  • Figure 24. Global DPT Vaccines share by Players (Top 3) 2022(%)
  • Figure 25. Global DPT Vaccines share by Players (Top 5) 2022(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Merck & Co., Inc. (United States) Revenue: by Geography 2022
  • Figure 29. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi (France) Revenue: by Geography 2022
  • Figure 31. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GSK (United Kingdom) Revenue: by Geography 2022
  • Figure 33. Wyeth (United States) Revenue, Net Income and Gross profit
  • Figure 34. Wyeth (United States) Revenue: by Geography 2022
  • Figure 35. Serum Institute of India Pvt. Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 36. Serum Institute of India Pvt. Ltd. (India) Revenue: by Geography 2022
  • Figure 37. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 39. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 40. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 41. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 42. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 43. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 44. AstraZeneca (United Kingdom) Revenue: by Geography 2022
  • Figure 45. Emergent BioSolutions Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 46. Emergent BioSolutions Inc. (United States) Revenue: by Geography 2022
  • Figure 47. Astellas Pharma, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 48. Astellas Pharma, Inc. (Japan) Revenue: by Geography 2022
  • Figure 49. Global DPT Vaccines: by Type USD Million (2023-2028)
  • Figure 50. Global DPT Vaccines: by Application USD Million (2023-2028)
  • Figure 51. Global DPT Vaccines: by Vaccine Type USD Million (2023-2028)
  • Figure 52. Global DPT Vaccines: by End-User USD Million (2023-2028)
  • Figure 53. South America DPT Vaccines Share (%), by Country
  • Figure 54. Asia Pacific DPT Vaccines Share (%), by Country
  • Figure 55. Europe DPT Vaccines Share (%), by Country
  • Figure 56. MEA DPT Vaccines Share (%), by Country
  • Figure 57. North America DPT Vaccines Share (%), by Country
  • Figure 58. Global DPT Vaccines: by Type K Tons (2023-2028)
  • Figure 59. Global DPT Vaccines: by Application K Tons (2023-2028)
  • Figure 60. Global DPT Vaccines: by Vaccine Type K Tons (2023-2028)
  • Figure 61. Global DPT Vaccines: by End-User K Tons (2023-2028)
  • Figure 62. South America DPT Vaccines Share (%), by Country
  • Figure 63. Asia Pacific DPT Vaccines Share (%), by Country
  • Figure 64. Europe DPT Vaccines Share (%), by Country
  • Figure 65. MEA DPT Vaccines Share (%), by Country
  • Figure 66. North America DPT Vaccines Share (%), by Country
  • Figure 67. Global DPT Vaccines: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Merck & Co., Inc. (United States)
  • Sanofi (France)
  • GSK (United Kingdom)
  • Wyeth (United States)
  • Serum Institute of India Pvt. Ltd. (India)
  • Pfizer Inc. (United States)
  • Johnson & Johnson (United States)
  • Novartis AG (Switzerland)
  • AstraZeneca (United Kingdom)
  • Emergent BioSolutions Inc. (United States)
  • Astellas Pharma, Inc. (Japan)
Additional players considered in the study are as follows:
Chiron Pharmaceutical Pvt Ltd (India) , Lanzhou Institute of Biological Products (China)
Select User Access Type

Key Highlights of Report


Dec 2023 211 Pages 95 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global DPT Vaccines research Quantitative research analysis
Global DPT Vaccines research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Merck & Co., Inc. (United States), Sanofi (France), GSK (United Kingdom), Wyeth (United States), Serum Institute of India Pvt. Ltd. (India), Pfizer Inc. (United States), Johnson & Johnson (United States), Novartis AG (Switzerland), AstraZeneca (United Kingdom), Emergent BioSolutions Inc. (United States) and Astellas Pharma, Inc. (Japan) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Advancements in Vaccine Delivery Devices " is seen as one of major influencing trends for DPT Vaccines Market during projected period 2022-2028.
The DPT Vaccines market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global DPT Vaccines research Report?

Have a Query? Click Here

Other Related Reports

Pharmaceutical Hot Melt Extrusion Comprehensive Study by Type (Single Screw Extruder, Twin Screw Extruder, Laboratory Extruder, RAM Extruder), End User (Research Laboratory, Contract Manufacturing Or...
$ 3350
Necrotizing Fasciitis Comprehensive Study by Application (Hospital & Clinics, Surgical Centers), Treatment (Surgical debridement, Antibiotics, Amputation), Diagnosis (Clinical examination, Blood and ...
$ 3800
Colorectal Cancer Drugs Comprehensive Study by Application (Radiotherapy, Chemotherapy), Drug Type (Bevacizumab, Irinotecan Hydrochloride, Capecitabine, Cetuximab, Ramucirumab, Oxaliplatin, Cetuximab...
$ 3650
Endometriosis Drugs Comprehensive Study by Application (Hospitals, Clinics, Research Institutes, Others), Route of Administration (Oral, Nasal Spray, Intrauterine Systems, Parenteral), Therapy Type (...
$ 3750
Azacitidine Drug Comprehensive Study by Type (Acute myeloid leukemia (AML), Myelodysplastic syndrome (MDS)), Application (Refractory anemia (RA), Refractory anemia with excess blasts (RAEB), Chronic ...
$ 3750
Angina Pectoris Drugs Comprehensive Study by Type (Nitrates, Non-Steroidal Anti-Inflammatory Drugs, Anti-Platelet Drugs, Beta Blockers, Statins, Calcium Antagonists, Angiotensin-Converting Enzyme (Ac...
$ 3750